Johnson & Johnson To Showcase Latest Advances Across Its Electrophysiology Portfolio At 2026 HRS Annual Meeting, Including New Evidence In PFA, And Cardiac Mapping & Imaging

As Johnson & Johnson celebrates 30 years of CARTO, the launch of CARTOSOUND SONATA brings new AI-based imaging and mapping capabilitiesi to electrophysiologyA total of 17 abstracts will be presented, including new

Semiconductors Look Dangerously Overheated After Massive Run: Analyst

After a 13-day NASDAQ rally, BTIG's Jonathan Krinsky analyzes market risks and shares where to find better risk-reward opportunities today.

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson

MeiraGTx reacquires bota-vec from Johnson & Johnson, outlining regulatory plans, funding outlook, and updated xerostomia data.

Barclays Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to $255

Barclays analyst Matt Miksic maintains Johnson & Johnson (NYSE:JNJ) with a Equal-Weight and raises the price target from $234 to $255.

These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results

Johnson & Johnson (NYSE:JNJ) reports upbeat earnings for Q1, with higher sales and raised fiscal 2026 guidance. Some analysts raise price targets.

Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst

Johnson & Johnson reports strong Q1, beating expectations and setting the stage for future growth. Analysts maintain Buy rating.

Stifel Maintains Hold on Johnson & Johnson, Raises Price Target to $250

Stifel analyst Rick Wise maintains Johnson & Johnson (NYSE:JNJ) with a Hold and raises the price target from $220 to $250.

Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $263

Wells Fargo analyst Larry Biegelsen maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $240 to $263.

Transcript: Johnson & Johnson Q1 2026 Earnings Conference Call

Johnson & Johnson Q1 2026 Earnings Call Transcript

Johnson & Johnson (NASDAQ: JNJ) reported first-quarter financial results on Tuesday. The transcript from the company's first-quarter earnings call has been provided below.

Johnson & Johnson Q1 Performance: Cancer Drug Revenue Grows, Free Cash Flow Falls, Hikes Dividend

Johnson & Johnson Q1 pharma growth offsets immunology decline; company raises guidance and extends dividend streak.

Earnings Scheduled For April 14, 2026

Johnson & Johnson Raises FY2026 Adj EPS Guidance from $11.43-$11.63 to $11.45-$11.65 vs $11.54 Est; Raises FY2026 Sales Guidance from $100.000B-$101.000B to $100.300B-$101.300B vs $100.575B E

Johnson & Johnson (NYSE:JNJ) raises FY2026 Adj EPS guidance from $11.43-$11.63 to $11.45-$11.65 vs $11.54 analyst estimate. Raises FY2026 sales outlook from $100.000 billion-$101.000 billion to $100.300 billion-$101.300

Johnson & Johnson Board Approves 3.1% Quarterly Dividend Hike To $1.34 Per Share, Payable June 9

At the new rate, the indicated dividend on an annual basis is $5.36 per share compared to the previous rate of $5.20 per share. The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the

Johnson & Johnson Q1 Adj. EPS $2.70 Beats $2.67 Estimate, Sales $24.062B Beat $23.630B Estimate.

Johnson & Johnson (NYSE:JNJ) reported quarterly earnings of $2.70 per share which beat the analyst consensus estimate of $2.67 by 1.12 percent. This is a 2.53 percent decrease over earnings of $2.77 per share from the

Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports

Four of the 30 Dow Jones Industrial Average stocks report this week. Here's a look at the companies and what the key figures to watch are.

ASML, JPMorgan And More Stocks With Earnings This Week

The Q1 earnings season gets underway this week with reports from major banks, including Goldman Sachs and JPMorgan and tech company ASML.

Morgan Stanley Maintains Overweight on Johnson & Johnson, Raises Price Target to $267

Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $262 to $267.

Johnson & Johnson To Present Data On Its FDA-Approved TECNIS PureSee Intraocular Lens At 2026 American Society Of Cataract And Refractive Surgery

Johnson & Johnson (NYSE: JNJ) will present data from two major studies supporting the performance of its recently FDA-approved TECNIS PureSee intraocular lens (IOL) at the 2026 American Society of Cataract and

Study Showing 50% Drop In COVID ER Visits Thanks To The Vaccine Put On Hold By CDC: Report

The CDC has reportedly delayed a report showing COVID-19 vaccine benefits, citing methodology concerns.

TD Cowen Assumes Johnson & Johnson at Buy, Announces Price Target of $250

TD Cowen analyst Michael Nedelcovych assumes Johnson & Johnson (NYSE:JNJ) with a Buy rating and announces Price Target of $250.

9 Health Care Stocks With Whale Alerts In Today's Session

Microsoft Is Now The Biggest Deadweight On S&P 500 — And Exxon Is What Nvidia Used To Be

Microsoft is the single biggest drag on the S&P 500 this year and all of the Magnificent 7 stocks are deadweight on headline returns. 

Johnson & Johnson Launches VARIPULSE Pro In Europe Following CE Mark Approval

The VARIPULSE Pro Platform features a new pulse sequence designed to streamline procedures and enhance workflow efficiencyi,iiVARIPULSE Pro to be featured at EHRA 2026 alongside VARIPURE 12-month interim data

Healthcare, Financials ETFs Get A Mega-Cap Reset With TRUF, TRUH

A closer look at VanEck's new TRUF and TRUH ETFs, designed to deliver cleaner healthcare and financials exposure with minimal tracking error.

Trump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: Report

According to a Bloomberg report, Trump may impose 100% tariffs on drugmakers without pricing deals, as part of a broader push to lower drug costs.

Reported Earlier: Johnson & Johnson Secures Permanent J-Code For INLEXZO, Streamlining Billing For BCG-Unresponsive Bladder Cancer Therapy

https://www.jnj.com/media-center/press-releases/inlexzo-gemcitabine-intravesical-system-assigned-permanent-billing-code-supporting-access-for-patients-with-certain-bladder-cancers

FDA Adverse Event Monitoring System Q4 2025 Flags Multiple Potential New Drug Safety Signals, Including Hypersensitivity, Hypogammaglobulinemia, Colitis, Aplastic Anemia And Rhabdomyolysis Un

https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda

RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $255 Price Target

RBC Capital analyst Shagun Singh reiterates Johnson & Johnson (NYSE:JNJ) with a Outperform and maintains $255 price target.

Royalty Pharma Announces R&D Co-Funding Agreement With Johnson & Johnson For Total Of $500M In 2026 And 2027 To Advance Development Of JNJ-4804, Investigational Medicine For Autoimmune Diseas

Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804,

Reported Saturday, Protagonist's ICOTYDE Demonstrates Increasing PASI 100 Rates Through Week 52 And Nearly 60% Complete Skin Clearance In Adolescents In Phase 3 ICONIC Program

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once-daily pill for moderate-to-severe plaque psoriasisResults further support theOne-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once-daily pill for moderat